What question did this study set out to answer?

This research aims to evaluate biochemical recurrence rates and clinical outcomes based on PSA doubling time in patients treated for non-metastatic prostate cancer.

May 1, 2026

Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer.

Key Points

This research aims to evaluate biochemical recurrence rates and clinical outcomes based on PSA doubling time in patients treated for non-metastatic prostate cancer.
Utilized the Optum® PC electronic medical record database involving 26,755 patients.
Categorized patients into those who underwent radical prostatectomy or radiation therapy.
Analyzed associations between patient characteristics, BCR risk groups, and time to BCR.
Found 122 patients had biochemical recurrence; high-risk patients (PSA-DT <12 months) had poorer outcomes.
Identified PSA and PSA-DT as strong predictors of biochemical recurrence.
Worse outcomes observed in high-risk groups with shorter doubling times.

Abstract

AIMS: We assessed the proportion of patients with biochemical recurrence (BCR), the occurrence of BCR in risk groups according to prostate-specific antigen doubling time (PSA-DT), and clinical outcomes in risk groups. PATIENTS AND METHODS: = 26,755) in the US using the Optum® PC electronic medical record database. Primary outcomes were the proportion of patients with BCR in prior radical prostatectomy (RP) or radiation therapy (RT) cohorts. Secondary outcomes included association between baseline characteristics and time to BCR, BCR risk group (high-risk: PSA-DT <12 months; low-risk: PSA-DT ≥12 months), and time from BCR to metastasis and castration-resistant PC (CRPC). RESULTS: = 122), respectively. CONCLUSIONS: PSA and PSA-DT are key predictors of BCR. Outcomes are worse among high-risk BCR patients with short PSA-DT.

AI에게 질문

Bookmark